室内生物技术/重组Api g 1（RP-AG1-1）/1/RP-AG1-1
市场价：
¥11500.00
美元价：
5750.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Allergen: | rApi g 1.0101 (Apium gravolens allergen 1.0101), celery |
| Unit: | 250µg |
| Source: | P. pastorsis |
| Mol. Wt: | ~16 kD |
| Purification: | Purified from Pichia pastoris culture by multi-step chromatography. Purity > 95% by silver stained SDS-PAGE, run under reducting condidtions. |
| Concentration: | See product insert. |
| Formulation: | Preservative and carrier free in 1X PBS buffer, pH 7.4 |
| Storage: | Store at -20ºC. Aviod repeated freeze-thaw cycles. |
| Notes: | (1)rApi g 1 has a C-terminal 6xHis-tag (2)Not tested for endotoxin. |
| Product Resources: | Recombinant Api g 1 Certificate of Analysis |
| Related products: | |
| Allergens are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. | |
| References: | |
| Hoffman-Sommergruber K, Ferris R, Pec M, Radauer C, O’Riordain G, Laimer Da Camarara Machado M, et al. Characterization of Api g 1.0201, new member of the Api g 1 family of celery allergens. Int Arch Allergy Immunol 2000;122(2):115-23. | |
| Hoffmann-Sommergruber K, Demoly P, Crameri R, Breiteneder H, Ebner C, Laimer Da Camara Machado M, et al. IgE reactivity to Api g 1, a major celery allergen, in Central European population is based on primary sensitization by Bet v 1. J Allergy Clin Immunol 1999;104:478-84. | |
| Hoffman-Sommergruber K, Vanek-Krebitz M, Ferris R, O’Riordain G, Susani M, Hirschwehr R, et al. Isolation and cloning of Bet v 1-homologous food allergens from celeriac (Api g 1) and apple (Mal d 1). Adv Exp Med Biol 1996;409:219-24 | |
| Breitenender H, Hoffmann-Sommergruber K, O’Riordain G, Sasani M, Ahorn H, Ebner C, et al. Molecular characterization of Api g 1, the major allergen of celery (Apium graveolens), and its immunological and structural relationships to a group of 17-kDa free pollen allergens. Eur J Biochem 1995;(15)233:484-9. | |
品牌介绍
indoor biotechnologies由前弗吉尼亚大学医学和微生物学教授，UVA哮喘和变态反应中心的成员Martin D. Chapman博士创立。Chapman博士是美国过敏，哮喘和免疫学研究院的院士，并曾担任美国国立卫生研究院，环境保护署，学术机构和《财富》 500强公司的顾问。室内生物技术专业生产抗过敏和哮喘的生物制剂。该公司是评估家庭，工作场所，学校和商业建筑中过敏原环境暴露的全球领导者。该公司生产用于过敏研究和诊断的高纯度过敏原，并在过敏原结构，功能和免疫识别方面的研究获得国际认可。室内生物技术的使命是改善过敏和哮喘患者的生活质量。
